Proven Intelligence Accelerating Next-Generation Therapies.

An effective Chemistry, Manufacturing, and Controls (CMC) strategy for lentiviral vectors (LVV) is built upon meticulous documentation. The batch record is the definitive legal and scientific account of the manufacturing process for a specific lot, providing the data integrity required for regulatory submissions and ensuring process reproducibility. A properly designed batch record system is a functional tool for process understanding and control.

Aligning Process Controls with Regulatory Expectations

For complex viral vectors, the manufacturing process defines the product. A batch record must capture every variable that can influence product quality. These variables encompass the quantities of plasmids and reagents, the specific equipment, environmental conditions, and the timing of each unit operation.

Our approach, conducted within a >100,000 sq ft facility, focuses on designing batch records that tell a clear story of process control. This level of documentation supports achieving an 18-24 month timeline to get candidates to IND.

Key Components of a Lentiviral Vector Batch Record

A robust LVV batch record is structured to ensure complete traceability and data integrity. The design anticipates the needs of both manufacturing operators and quality assurance reviewers.

• Raw Material Traceability: Verification and documentation of all starting materials, including plasmid identity, cell bank passage number, and media lot numbers.

• In-Process Controls (IPCs): Defined checkpoints with clear acceptance criteria for monitoring key process parameters like cell density, pH, and vector titer at intermediate stages.

• Equipment & Environmental Logs: Automated and manual records of equipment calibration, sterilization, and use, alongside cleanroom environmental monitoring data.

• Deviation & Investigation Reporting: A formal system for capturing any deviation from the MBR, documenting the investigation, and outlining corrective and preventive actions (CAPAs).

Pseudotype and Payload Considerations in Documentation

The specific biology of a lentiviral vector directly informs its manufacturing process and, consequently, its documentation requirements. Early-stage investigations demonstrating how different pseudotypes influence tissue transduction (PMID: 12231171) or how vectors can achieve sustained transgene expression (PMID: 12778376) highlight the need for precise process control. These biological outcomes are directly linked to manufacturing inputs.

The batch record must be designed to capture the specific parameters dictated by these choices. For example, the use of a VSV-G pseudotype necessitates different purification column specifications and analytical release assays than other envelope proteins. These details are codified within the MBR to ensure consistency from batch to batch.

Translating these complex biological requirements into a compliant and functional batch record requires specialized expertise across all facets of vector production and analytics.

From Record to Readiness: Supporting IND Submissions

Well-designed batch records are a cornerstone of a successful IND filing. While Franklin Biolabs as a brand launched in 2024, our scientific leadership’s work has contributed to a 100% successful IND rate for programs since 2019. This record is built on a deep understanding of regulatory expectations for CMC data packages.

The complete set of executed batch records for toxicology and engineering runs provides the objective evidence that the manufacturing process is robust and under control. Strategic Documentation Systems Accelerating Audit Readiness ensure that when regulators review the submission, the data is clear, defensible, and complete.